Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Barry

Showing results (611-620 of 674) with videos related to

Pageof 68
Sort By:
Eneurologicalsci|August 29, 2024
Epileptic seizures revealing tuberous sclerosis in a tropical environment: A study of 12 case seriesSouleymane M'Bara Diallo, Mamadou Diallo, I S Barry, et al.
Nature Cancer|September 7, 2023
Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDACXu Zhou, Jingyu An, Roma Kurilov, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 25, 2010
Interactome analysis of longitudinal pharyngeal infection of cynomolgus macaques by group A StreptococcusPatrick R Shea, Kimmo Virtaneva, John J Kupko, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 19, 2011
Protein microarray analysis of mammary epithelial cells from obese and nonobese women at high risk for breast cancer: feasibility dataPatrick G Pilie, Catherine Ibarra-Drendall, Michelle M Troch, et al.
European Journal of Cancer (Oxford, England : 1990)|July 6, 2019
Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trialsM Martín, S Loibl, T Hyslop, et al.
Bioorganic & Medicinal Chemistry Letters|May 12, 2012
Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting α5β1: part 1Bénédicte Delouvrié, Katherine Al-Kadhimi, Jean-Claude Arnould, et al.
Bioorganic & Medicinal Chemistry Letters|May 11, 2012
Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting α5β1: part 2Bénédicte Delouvrié, Katherine Al-Kadhimi, Jean-Claude Arnould, et al.
Blood|February 17, 2017
Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCLTabea Erdmann, Pavel Klener, James T Lynch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2016
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancerU A Matulonis, G M Wulf, W T Barry, et al.
Cancer Research|December 5, 2024
Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in MelanomaCatriona A Ford, Dana Koludrovic, Patricia P Centeno, et al.
Pageof 68

Showing results (611-620 of 674) with videos related to

Sort By:
Pageof 68
Eneurologicalsci|August 29, 2024
Epileptic seizures revealing tuberous sclerosis in a tropical environment: A study of 12 case seriesSouleymane M'Bara Diallo, Mamadou Diallo, I S Barry, et al.
Nature Cancer|September 7, 2023
Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDACXu Zhou, Jingyu An, Roma Kurilov, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 25, 2010
Interactome analysis of longitudinal pharyngeal infection of cynomolgus macaques by group A StreptococcusPatrick R Shea, Kimmo Virtaneva, John J Kupko, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 19, 2011
Protein microarray analysis of mammary epithelial cells from obese and nonobese women at high risk for breast cancer: feasibility dataPatrick G Pilie, Catherine Ibarra-Drendall, Michelle M Troch, et al.
European Journal of Cancer (Oxford, England : 1990)|July 6, 2019
Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trialsM Martín, S Loibl, T Hyslop, et al.
Bioorganic & Medicinal Chemistry Letters|May 12, 2012
Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting α5β1: part 1Bénédicte Delouvrié, Katherine Al-Kadhimi, Jean-Claude Arnould, et al.
Bioorganic & Medicinal Chemistry Letters|May 11, 2012
Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting α5β1: part 2Bénédicte Delouvrié, Katherine Al-Kadhimi, Jean-Claude Arnould, et al.
Blood|February 17, 2017
Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCLTabea Erdmann, Pavel Klener, James T Lynch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2016
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancerU A Matulonis, G M Wulf, W T Barry, et al.
Cancer Research|December 5, 2024
Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in MelanomaCatriona A Ford, Dana Koludrovic, Patricia P Centeno, et al.
Pageof 68